Consistent with this, neuronal overexpression of SELENOK in AD mice alleviated synaptic deficits, implicating GluA2 palmitoylation as a potential mechanism underlying the therapeutic effects of Se in AD. The gene discussed is GRIA2; the disease is Alzheimer disease.